Since its initial description in 1971 (ref. 1), more than 60 cases of Johanson-Blizzard syndrome (JBS) have been reported. In addition to its pathognomonic features of congenital exocrine pancreatic insufficiency and nasal wing aplasia (Fig. 1a) , JBS includes several facultative abnormalities, including scalp defects, imperforate anus, deafness, hypothyroidism, dental defects, genitourinary malformations and mental retardation 1, [8] [9] [10] [11] [12] [13] [14] [15] . Identification of seven cases of JBS in a European population-based study on imperforate anus 16 , which occurs in 40% of individuals with JBS, suggests that the incidence of JBS is B1 in 250,000.
To identify the locus mutated in JBS, we undertook a genome-wide linkage scan using a panel of microsatellite markers with average distance of 10 cM in seven kindreds with JBS ( Supplementary Fig. 1 online). We identified a region of homozygosity on chromosome 15q shared by individuals originating from all consanguineous families. We further analyzed this region by typing additional microsatellite markers from the draft human genome sequence and refined the candidate region to a 7.5-cM interval between the flanking markers D15S1012 and D15S659. The maximum two-point lod score was 4.8 for y ¼ 0 at D15S968 (Supplementary Table 1 online). We prioritized genes for mutational screening on the basis of putative function and expression data but identified no obvious candidate. By high-throughput direct sequencing of DNA from individuals with JBS, we eventually detected mutations in the gene UBR1. UBR1 spans B161 kb, contains 47 exons and encodes one E3 ubiquitin (Ub) ligase of the N-end rule pathway (Fig. 1b,c) . In affected individuals from 12 of 13 families included in our study, the variations likely to be causal mutations were identified on both alleles of UBR1, whereas in one family, only the paternally inherited mutation was found ( Table 1) . Most disease-associated UBR1 alleles (12 of 14) were mutations that predicted premature translational stop codons. Two missense mutations in UBR1 caused substitutions of residues that are conserved among UBR1 proteins of different species (Fig. 1d,e) . One of these missense mutations, H136D, affected a conserved motif in the region of UBR1 previously found to be important for substrate binding 3 and was therefore likely to perturb the activity of UBR1. Two apparently unrelated and nonconsanguineous families originating from the same district in Costa Rica shared the same homozygous mutation Q513X. Haplotype analysis in these families provided evidence of a common ancestor (data not shown). In each family, the UBR1 mutations segregated with the disease phenotype. None of the mutations was detected among 192 control chromosomes.
Using antibody to UBR1 and either immunofluorescence microscopy with pancreatic tissue sections or immunoblotting with extracts from cells in culture, we observed no UBR1 protein in individuals with JBS from different families, confirming that loss of UBR1 function is the mechanism underlying this disease (Fig. 2a,d ). By contrast, UBR1 was readily detectable in control pancreas, where it was present largely in the cytosol of acinar cells (Fig. 2b) . Control immunostaining for trypsinogen as a specific marker for acinar cells showed no substantial differences between pancreas from controls and individuals with JBS (Fig. 2c,e) , indicating that there was no primary defect of zymogen synthesis in JBS.
The N-end rule pathway is a part of the Ub-proteasome system [2] [3] [4] [5] [6] [7] 17 . Regulated protein degradation by this system controls the levels of many intracellular proteins 18, 19 . A substrate of the Ub system is conjugated to Ub through the action of three enzymes, E1, E2 and E3; the latter group is an exceptionally large set of proteins 18, 19 . A ubiquitylated protein bears a covalently linked poly-Ub chain and is degraded by the 26S proteasome 18 . The selectivity of ubiquitylation is determined mainly by E3, which recognizes a substrate's degradation signal (degron) 4, 18 . We found that UBR1 is another of the E3 Ub ligases that are implicated in the pathogenesis of human genetic diseases. These E3 ligases include UBE3A, mutant in Angelman Figure 1 Clinical phenotype and UBR1 mutations in JBS. (a) Typical clinical appearance of JBS with aplasia of the nasal wings in an 8-y-old female. (b) Exon-intron structure of UBR1, containing 47 exons (blue vertical bars). Sites of the mutations observed in JBS are indicated by arrows above for truncating mutations and below for two missense mutations (c). The UBR1 protein contains several distinct regions, including the UBR box (a substrate-binding domain), which is highly conserved among UBR family members 3 , and the cysteine-and histidine-rich RING (RING-H2) domain, which is present in a larger class of E3 Ub ligases 6, 7, 28 . Regions III and IV denote sequences that are highly conserved among UBR1 and UBR2 in different species. ClpS denotes a region of sequence similarity to prokaryotic ClpS, an accessory subunit that contributes to recognition of degrons by the ATP-dependent protease ClpAP 29 . BRR (basic residue-rich region) denotes a conserved motif that contributes to the binding of yeast UBR1 to the E2 enzyme RAD6 (refs. 28,30) . (d,e) Sequence alignments of two regions of human UBR1 with its orthologs in different species and with human UBR2. (d) The highly conserved residue His136 mutated in one case of JBS is located in the conserved zinc finger-like motif [C-X 12 -]C-X 2 -C-X 5 -C-X 2 -C-X 2 -C-X 5 -H-X 2 -H-X 12-14 -C-X 11 -C, called the UBR box. (e) Gly1279, a residue of UBR1 mutated in another case of JBS, is located in a region of unknown function. The sequence context of Gly1279 in human UBR1 is less conserved than that of His136; the former context is different in putative Drosophila melanogaster UBR1 and in human UBR2. Black and gray shading indicates identical and similar residues, respectively. Hs, Homo sapiens; Mm, Mus musculus; Gg, Gallus gallus; Dm, Drosophila melanogaster; Ce, Caenorhabditis elegans; Sc, Saccharomyces cerevisiae. [18] [19] [20] . The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue 3, 4, 7, 17 . It has a hierarchic structure: some destabilizing N-terminal residues are enzymatically modified before they are recognized by the pathway's Ub ligases, including UBR1. Known functions of the N-end rule pathway include control of peptide import (through conditional degradation of import's repressor), regulation of apoptosis (through degradation of a caspaseprocessed inhibitor of apoptosis), fidelity of chromosome segregation (through degradation of a conditionally produced fragment of cohesin), regulation of meiosis and cardiovascular development 2, 3, 6, 7, 17 .
Mammalian UBR1 contains distinct binding sites for basic (type 1) and bulky hydrophobic (type 2) N-terminal residues of substrates, as well as a third binding site for substrates bearing internal (non-Nterminal) degrons 3, 4, 6, 7, 17 . The family of mouse (and human) UBR proteins, which contain a common substrate-binding domain called the UBR box, consists of at least four E3 ligases, including UBR1 and UBR2 (ref.
3). The latter have similar substrate-binding properties 6, 7 . Functional overlaps among these E3 ligases probably underlie the viability of single-mutant mice 6, 7 (Ubr1 -/-and Ubr2 -/-) and the more severe but still nonlethal phenotype of individuals with JBS. Double mutant Ubr1 -/-Ubr2 -/-mice undergo early embryonic lethality 3, 6 .
We examined the possibility that aspects of the JBS phenotype might stem from reduced expression of (possibly) UBR1-complementing UBR2 E3 ligase in organs most prominently affected in JBS. But the two genes were expressed at similar levels in all tissues that we examined, including adult and fetal pancreas ( Supplementary Fig. 2 online). These results suggested that the phenotypes of JBS may be caused by molecular perturbations that were specific to the absence of UBR1, as they could not be rescued by UBR2.
To address further the pathogenesis of JBS, we focused on exocrine pancreas, an organ most consistently affected in this disease 21 . Autopsy findings previously suggested that exocrine pancreatic insufficiency in individuals with JBS was caused by selective loss of acinar cells 8, 10, 13 , but details of this process remained to be elucidated. We examined pancreatic pathology and cell biology in autopsy specimens from two fetuses (21 and 34 weeks of gestation, respectively) and also in a newborn baby with JBS. The pancreas of individuals with JBS showed acinar tissue loss that increased with gestational age and was accompanied by inflammatory infiltrates, most prominent in the near-term fetus (Fig. 3) . Using the TUNEL assay for apoptotic cells, we found no evidence of increased apoptosis in acinar cells of individuals with JBS (data not shown). Taken together, these findings suggest that the main pancreatic defect in individuals with JBS is not perturbed acinar development in early embryogenesis, but rather gradual destruction of previously formed acinar cells in maturing fetuses, a process that resembles pancreatitis of intrauterine onset. To analyze molecular aspects of perturbations in JBS that would be difficult or impossible to address in human autopsy material, we used Ubr1 -/-mice 3, 6, 7 . These mice were viable and fertile and lacked substantial phenotypic abnormalities other than reduced weight (by 10-20%, with disproportionate decreases in skeletal muscle and adipose tissue) 7 . To examine whether malnutrition due to exocrine pancreatic insufficiency could be one cause of reduced weight of Ubr1 -/-mice, we determined fecal chymotrypsin and elastase activity and detected impaired pancreatic exocrine function (Fig. 4a) . We excluded the possibilities that synthesis of trypsinogen and proelastase was markedly reduced and that defects in their activation caused the pancreatic impairment by measuring protein content and pancreatic tissue activities of these enzymes in Ubr1 -/-and wild-type mice (data not shown). In addition, we observed no substantial morphological differences between the pancreas of Ubr1 -/-versus wild-type mice under control conditions, by either light or electron microscopy (Fig. 4b,c and data not shown) .
To address these issues further, we prepared pancreatic acini (the functional assemblies of exocrine cells) from Ubr1 -/-and wild-type mice and exposed them in vitro to increasing concentrations of the physiological secretagogue cholecystokinin 22 . Pancreas of Ubr1 -/-mice was considerably (B100 times) less responsive to stimulation (Fig. 4d) . This difference probably accounts for the observed metabolic defect and pancreatic insufficiency in Ubr1 -/-mice and suggests that a signaling circuit that couples the secretion of pancreatic enzymes to the level of a secretion-causing compound is controlled by the N-end rule pathway. Further analysis used an in vivo model of acinar cell stress and experimental pancreatitis in which supraphysiological concentrations of secretagogue result in a 'paradoxical' block of pancreatic secretion 23 . We found that this treatment led to a more severe injury of Ubr1 -/-pancreas, compared with wild-type, with prominent necrosis in the former, as indicated by histological evidence, serum amylase levels and other parameters of local pancreatic injury or systemic inflammatory response 23 (Fig. 4e-j) . These results strongly suggest that the intact (as distinguished from UBR1-deficient) N-end rule pathway contributes to pancreatic homeostasis and defense against noxious stimuli in pancreatic acinar cells.
Taken together, our findings in UBR1-deficient mice and humans are consistent with the hypothesis that specific targets of UBR1 in the pancreas may include zymogens or their derivatives and molecules involved in their intracellular processing or export. The observed difference in phenotypic severity of UBR1 deficiency between human JBS and its mouse Ubr1 -/-counterpart 3,6,7 may stem from speciesspecific differences in functional overlaps among Ub ligases of the N-end rule pathway. The phenotypic defects in JBS involve, in a consistently recurring pattern, several organ systems in addition to pancreas 1, [8] [9] [10] [11] [12] [13] [14] [15] . We suggest that UBR1-mediated protein degradation has a crucial role at certain stages of human development, in specific cell types, and that in those settings, this role cannot be effectively taken on by other E3 ligases of the N-end rule pathway. Further advances in understanding JBS will require identification of specific UBR1 substrates whose levels or functions are perturbed in the absence of UBR1 in ways that underlie the pathogenesis of JBS.
METHODS
Subjects. This study was approved by the University of Erlangen-Nuremberg Institutional Review Boards. We obtained blood samples and pedigrees after receiving informed consent from the parents or caretakers of the individuals affected by JBS. We extracted genomic DNA using standard procedures. From deceased individuals and aborted fetuses, we obtained DNA from stored biopsy specimens, either cryoconserved or paraffin-embedded. Several of our subjects were previously reported ( Table 1) . Of the 15 families diagnosed with JBS that we studied, two were excluded from further study: in one case, only paraffin-embedded fixed tissue that did not yield DNA of acceptable quality This treatment is known to lead to a paradoxical block of pancreatic secretion and intracellular zymogen activation, eventually resulting in acinar cell necrosis and local as well as systemic inflammatory response 23 .
Compared with wild-type mice (e), Ubr1 -/-mice (f) had increased areas of necrotic cells (yellow dashed line). Consistent with these findings, serum amylase levels were significantly higher in Ubr1 -/-mice (g). In pancreatic homogenates from Ubr1 -/-mice treated with cerulein, we also found significantly higher trypsin activity, in comparison with identically treated wild-type mice, but there was no increased spontaneous trypsin activity in untreated Ubr1 -/-mice versus wild-type mice (h). Quantification of MPO activity in pancreatic homogenates and the lungs, reflecting, respectively, local and systemic inflammatory responses to experimental pancreatitis, showed significantly increased MPO levels in Ubr1 -/-mice (i,j). For each group (n ¼ 6), error bars represent s.d.
was available from the index individuals, and the other case, there were concerns about the clinical diagnosis of JBS in the index individual. All other subjects had the unequivocal clinical picture of JBS, with congenital exocrine pancreatic insufficiency and severe hypoplasia or aplasia of the nasal wings (these two traits are the minimal diagnostic criteria).
Linkage analysis. We carried out the initial genome-wide linkage analysis in families JBS01-JBS04, JBS06 and JBS09 using Weber panel Version 10 (Research Genetics), ABI3100 sequence analyzer and Genotyper software v3.7 (Applied Biosystems). We achieved marker saturation using existing and newly generated microsatellite markers. We carried out two-point lod score calculations using the LINKAGE program package, with help from the computer programs LINKRUN and MKS, using an autosomal recessive, fully penetrant model.
Mutation analysis.
We identified candidate genes using the National Center for Biotechnology Information and University of California Santa Cruz human genome databases. We designed primers flanking each of the 47 exons of UBR1, as well as exons of other genes located in the critical interval, using standard software (Primer 3). Oligonucleotide sequences are given in Supplementary Table 2 online. We carried out bidirectional direct sequencing using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) and a ABI3730 capillary sequencer (Applied Biosystems). We evaluated the sequences using the DNA Star software.
Antibodies. We used a previously described 7 affinity-purified, peptide-mediated antibody to mouse UBR1, which is known to cross-react with human UBR1 (ref. 24) . We used fluorescein isothiocyanate-conjugated mouse monoclonal antibody to human CD45 (Leukocyte Common Antigen) to label leukocytes in paraffin sections (BD Pharmingen, clone OX-1). We used a polyclonal antibody to human cationic trypsinogen from Chemicon International. We purchased mouse monoclonal antibody to human chymotrypsin from QED Bioscience.
Immunoblot analysis. We carried out immunoblot analyses with extracts from fibroblasts of individuals with JBS and JBS-derived lymphoblastoid cell lines versus wild-type controls. Equal amounts of total protein were separated by SDS-PAGE using NuPAGE 3-8% Tris Acetate Gel (Invitrogen), transferred to nitrocellulose membranes and probed with antibodies, using standard protocols and ECL-based detection with a Lumi-Imager F1 (Roche), in accordance with the manufacturer's instructions. We used immunoblotting with antibody to b-actin (Abcam) as a loading control.
Quantification of UBR1 and UBR2 expression using real-time RT-PCR. We isolated total RNA from human tissues using Trizol Reagent (Invitrogen) and synthesized cDNA using the SuperScript III One
Step RT-PCR System (Invitrogen). We carried out real-time quantitative PCR in accordance with the manufacturer's instructions, using ABI PRISM 7900 (Applied Biosystems) and Assay-on-Demand TaqMan probe and primers (Hs00233297_m1 for UBR1 and Hs00322358_m1 for UBR2). All reactions were run in triplicate.
We calculated the levels of a target mRNA relative to two different reference mRNAs (ACTB and B2M). Assuming an efficiency of 2 (relative increase in template mRNA required to decrease by 1 the number of cycles), we calculated the relative expression ratios as R ¼ 2 (Ct(control) -Ct(test)) , where Ct is the cycle number at threshold.
Animals. For animal studies, we used a previously constructed strain of Ubr1 -/-mice, in the C57BL6/129 mixed background 7 . Wild-type littermates served as controls. All animal studies were approved by the Animal Use and Care Committee of the University of Greifswald.
In situ RNA hybridization. We cloned B500-bp cDNA fragments into pCRII using the TA Cloning kit (Invitrogen). The resulting plasmid was digested with XbaI and then transcribed with SP6 RNA Polymerase (Roche). We selected the PCR-produced probes using the sequences of human UBR1 (nucleotides (nt) 4,697-5,181) and UBR2 (nt 4,712-5,198) and of mouse Ubr1 (nt 4,984-5,486) and Ubr2 (nt 4,839-5,270), choosing regions that yielded low scores in similarity comparisons among the UBR family members. We carried out in situ hybridization for mouse and human UBR1 and UBR2 with dissected pancreas of C57BL6 newborn mice and also with adult human pancreas obtained from a pancreatectomy specimen. We cut tissues into 10-mm-thick cryosections and examined them on Superfrost/Plus Microscope slides (Fisher Scientific). Additional probes derived from different parts of the human and mouse genes yielded similar results. Negative control probes yielded no specific hybridization in pancreas tissue (data not shown).
Induction of acute pancreatitis by cerulein. We induced pancreatitis in 6-to 8-week-old Ubr1 -/-mice and wild-type littermates weighing 20-24 g. After fasting mice for 18 h, with access to water ad libitum, we administered the secretagogue cerulein (Pharmacia Biotech AB) using seven intraperitoneal injections of 50 mg per kg of body weight at hourly intervals, as described previously 23 . As controls, we used mice injected with saline solution. After exsanguination under ether anesthesia, the pancreas was rapidly removed, the fat was trimmed off, and the pancreas was either fixed in 5% formaldehyde for electron microscopy or embedded in paraffin. The main part of pancreas was frozen in LN 2 and stored at -80 1C until further analyses. Lung tissue was either fixed in 5% formaldehyde for morphology studies or snap-frozen in LN 2 .
Amylase secretion assay. We carried out amylase secretion experiments as described previously 25 . Pancreas from male Ubr1 -/-or wild-type mice was digested with purified collagenase (Collagenase Serva), mechanically dispersed and passed through a mesh nylon cloth. We incubated acini for 30 min at 37 1C with cholecystokinin (biologically active phosphorylated CCK octapeptide ([Tyr(SO3H)27]-cholecystokinin fragment; Sigma) at concentrations of 1 pM to 10 mM. We used unstimulated acini as controls. We measured amylase content in cell pellets and supernatants after lysing cells with ice-cold lysis buffer, using an amylase-mediated color reaction and ET-G 7 PNP as a substrate (Amyl Kit; Roche). Amylase activity was expressed as a percentage of total amylase activity in the cells. Each group of assays comprised four independent experiments, and measurements were made in triplicate.
Immunofluorescence analysis in paraffin sections. We removed the paraffin from sections (2-to 4-mm) of paraffin-embedded tissues using standard procedures and processed them for immunolabeling as described 26 . We carried out immunostaining for trypsin, chymotrypsin, UBR1 and CD45. We detected apoptosis using the ApopTag Fluorescein in situ detection kit (S7110, Chemicon) in accordance with the manufacturer's instructions. This assay detects apoptotic cells in situ by the indirect TUNEL method. We counterstained nuclei using DAPI. We also stained paraffin-embedded sections with hematoxylin and eosin. We used a Zeiss Axiophot microscope connected to MR color digital camera for morphometric evaluation.
Electron microscopy. We fixed small blocks (2 mm in diameter) of pancreatic tissue from individuals with JBS or from pancreatitic and control mice in 2% formaldehyde-2% glutaraldehyde for Epon embedding, followed by osmium, uranyl and lead staining for electron microscopy of thin sections. Samples were examined using a Philips 400 electron microscope, as described 26 .
Myeloperoxidase activity in lung and pancreatic homogenates. We processed tissues as previously described 23 . We homogenized pancreas or lung tissue and resuspended the pellet in 50 mM K-phosphate buffer (pH 6.0) containing 0.5% cetyltrimethylammoniumbromide. We measured myeloperoxidase (MPO) activity using 0.53 mM O-dianisidine and 0.15 mM H 2 O 2 as substrates. We monitored the increase in A 460 at room temperature, using a Dynatech MR 5000 Elisa reader. The results are expressed as units of MPO activity, with 1 unit corresponding to oxidation of 1 mmol H 2 O 2 per min per mg of pancreatic protein.
Amylase serum levels. We collected blood by aortic puncture during killing of mice. We produced serum using standard procedures and stored it at -20 1C.
We measured the activity of serum a-amylase using 4.6-ethylidene-(G7)-1-4-nitrophenyl-(GI)-a, D-maltoheptaoside (EPS method) in accordance with the manufacturer's protocol (Roche).
Detection of chymotrypsin and elastase in mouse feces. We collected the feces of Ubr1 -/-mice and their wild-type littermates (fed standard chow) and stored it at -20 1C. We suspended samples of 15-30 mg in sample solvent (0.1% Triton X-100, 0.5 M NaCl and 100 mM CaCl 2 ), briefly sonicated them and centrifuged them at 20,000 r.p.m. for 10 min at 0 1C.
We subjected the supernatant to fluorometric analysis. We used 10 mM
